Terpene Science Could Help Cannabis Brands Build More Consistent Products
Terpenes are volatile plant compounds best known for the aromas and flavors they contribute to cannabis. More than 200 cannabis terpenes have been reported, although only a smaller group appears regularly in commercial flower. Their concentrations vary with genetics, cultivation, harvest timing, processing, and storage—making terpene analysis potentially useful for brands seeking to produce more consistent products.
That opportunity extends beyond flavor. Researchers are investigating whether particular combinations of cannabinoids and terpenes are associated with different consumer experiences or biological effects. The evidence is still developing, and terpene profiles cannot yet be treated as reliable medical prescriptions. But chemical profiling may offer a more meaningful way to describe cannabis products than strain names or broad labels such as “indica” and “sativa.” A study of more than 800 commercial cannabis varieties, for example, found that cultivar names were not always good indicators of underlying chemistry, while terpene profiles were associated with reported flavor and subjective effects. The researchers’ findings on cannabis varieties and chemical composition illustrate why chemovar-based labeling may be more informative.
One frequently cited example of data-driven terpene formulation is NT-VRL-1, a proprietary blend developed from compounds selected for potential antiviral activity. In a 2021 in-vitro study, researchers tested the formulation, with and without CBD, against human coronavirus 229E in cultured human lung fibroblast cells. The formulation contained 30 terpenes, with beta-caryophyllene, eucalyptol, and citral among its main constituents. The combination of NT-VRL-1 and CBD improved cell viability compared with some individual treatments and positive controls in that laboratory model.
A follow-up study published in 2024 expanded the testing to human coronavirus OC43 and influenza A, as well as inflammatory signaling in peripheral blood mononuclear cells. The researchers reported antiviral and cytokine-inhibiting effects in the tested cell systems, with CBD strengthening some—but not all—of the observed responses. However, the work remained preclinical and in vitro. It did not demonstrate that NT-VRL-1 or CBD can prevent or treat COVID-19 in people, nor did it establish that the formulation is more effective than dexamethasone in patients. The comparison with dexamethasone involved laboratory concentrations and should not be interpreted as a clinical treatment comparison. Dexamethasone remains an evidence-based therapy for selected patients with severe or critical COVID-19 under medical supervision, as outlined by the World Health Organization.
Terpene research may also help address a more practical industry problem: preserving a product’s chemical identity from harvest to sale. Monoterpenes are especially volatile and can be lost or transformed during drying, heating, extraction, and storage. In one accelerated stability study, researchers found that adding terpene blends to packaged cannabis inflorescence reduced the loss of THC compared with untreated samples. The experiment used hydrogen peroxide to speed oxidative degradation, so its results should not be assumed to predict ordinary shelf life, but it demonstrates how terpenes might be studied as part of packaging and preservation strategies. The published storage study is available through PubMed.
Processing can change terpene profiles as well. Research on medical cannabis inflorescences found that steam exposure affected different terpenes in different ways, with some volatile compounds declining and others appearing as likely breakdown products. These findings reinforce the need to measure finished products rather than assume that an extract, vape, edible, or flower product retains the exact profile of its starting material. The Scientific Reports study on processing and terpene levels provides one example of how manufacturing conditions can alter cannabis chemistry.
For cannabis brands, the commercial value of terpene science is therefore less about promising a guaranteed “sleep,” “calm,” or “energy” effect and more about improving transparency and repeatability. Detailed certificates of analysis, standardized terpene measurements, controlled processing, and clear distinction between naturally occurring and added terpenes could help consumers compare products more meaningfully.
The therapeutic potential of terpenes remains an active area of research, but much of the strongest evidence is still limited to cell, animal, observational, or small exploratory studies. Brands that present these findings responsibly can use terpene data to support better product development without overstating what the science proves. The most credible future for cannabis formulation is likely to be data-driven and chemically characterized—but also careful about the difference between an interesting laboratory signal and a demonstrated human health benefit.
